Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-06-01
2001-06-05
Bansal, Geetha P. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007200, C435S007210, C435S007230, C435S007920, C435S040500, C435S040510, C424S130100, C424S133100, C424S141100, C424S142100, C424S152100, C424S155100, C424S172100, C424S174100
Reexamination Certificate
active
06242204
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to novel hybridoma cells secreting monoclonal antibodies against a lung cancer marker.
BACKGROUND OF THE INVENTION
Lung cancer is the most common form of cancer in the world. Typical diagnosis of lung cancer combines x-ray with sputum cytology. Unfortunately, by the time a patient seeks medical attention for their symptoms, the cancer is at such an advanced state it is usually incurable. Consequently, research has been focused on early detection of tumor markers before the cancer becomes clinically apparent and while the cancer is still localized and amenable to therapy.
The World Health Organization has classified lung cancer into four major histological or morphological types: (1) squamous cell carcinoma, (2) adenocarcinoma, (3) large cell carcinoma, and (4) small cell lung carcinoma. (World Health Organization. 1982. “The World Health Organization Histological Typing of Lung Tumors,”
Am J Clin Pathol
77:123-136). However, there is a great deal of tumor heterogeneity even within the various subtypes, and it is not uncommon for lung cancer to have features of more than one morphological subtype. The term “non-small cell lung carcinoma” (NSCLS) has been used to distinguish squamous carcinomas, adenocarcinomas, and large cell carcinomas from small cell lung carcinomas.
Particular interest has been given to the identification of antigens associated with lung cancer. These antigens have been used in screening, diagnosis, clinical management, and potential treatment of lung cancer. For example, carcinoembryonic antigen (CEA) has been used as a tumor marker of cancer including lung cancer. (Nutini, et al. 1990. “Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer,”
Int J Biol Markers
5:198-202). Squamous cell carcinoma antigen (SCC) is another established serum marker. (Margolis, et al. 1994. “Serum tumor markers in non-small cell lung cancer,”
Cancer
73:605-609). Other serum antigens for lung cancer include antigens recognized by monoclonal antibodies (MAb) 5E8, 5C7, and 1F10, the combination of which distinguishes between patients with lung cancer from those without. (Schepart, et al. 1988. “Monoclonal antibody-mediated detection of lung cancer antigens in serum,”
Am Rev Respir Dis
138:1434-8). Serum CA 125, initially described as an ovarian cancer-associated antigen, has been investigated for its use as a prognostic factor in NSCLC. (Diez, et al. 1994. “Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer,”
Cancer
73:136876). Other tumor markers studied for utilization in multiple biomarker assays for lung cancer include carbohydrate antigen CA19-9, neuron specific enolase (NSE), tissue polypeptide antigen (TPA), alpha fetoprotein (AFP), HCG beta subunit, and LDH. (Mizushima, et al. 1990. “Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay,”
Oncology
47:4348; Lombardi, et al. 1990. “Clinical significance of a multiple biomarker assay in patients with lung cancer,”
Chest
97:639-644; and Buccheri, et al. 1986. “Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma,”
Cancer
57:2389-2396).
Monoclonal antibodies (MAb) to the antigens associated with lung cancer have been generated and examined as possible diagnostic and/or prognostic tools. For example, MAbs for lung cancer were first developed to distinguish non-small cell lung carcinoma (NSCLC) which includes squamous, adenocarcinoma, and large cell carcinomas from small cell lung carcinomas (SCLC). (Mulshine, et al. 1983. “Monoclonal antibodies that distinguish non-small-cell from small-cell lung cancer,”
J Immunol
121:497-502). MAbs have also been developed as immunocytochemical stains for sputum samples to predict the progression of lung cancer. (Tockman, et al. 1988. “Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection,”
J Clin Oncol
6:1685-1693). U.S. Pat. No. 4,816,402 discloses a murine hybridoma monoclonal antibody for determining bronchopulmonary carcinomas and possibly adenocarcinomas. Other monoclonal antibodies utilized in immunohistochemical studies of lung carcinomas include MCA 44-3A6, L45, L20, SLC454, L6, and YH206. (Radosevich, et al. 1985. “Monoclonal antibody 44-3A6 as a probe for a novel antigen found on human lung carcinomas with glandular differentiation,”
Cancer Res
45:5808-5812).
Despite the numerous examples of isolated lung cancer antigens and subsequent production of MAb to these antigens, none has yet emerged that has changed clinical practice. (Mulshine, et al., “Applications of monoclonal antibodies in the treatment of solid tumors,” In:
Biologic Therapy of Cancer.
Edited by V. T. Devita, S. Hellman, and S. A. Rosenberg. Philadelphia: J B Lippincott, 1991, pp. 563-588). There is a continuing need to identify specific antigens associated with lung cancer and to generate monoclonal antibodies (MAb) to these antigens for the development of tools for diagnosing cancer, targeting of drugs and other treatments to particular sites in the body, imaging of tumors for radiotherapy, and possible generating therapeutic agents for cancer.
In U.S. Pat. No. 5,589,579 and U.S. Pat. No. 5,773,579, a lung cancer marker antigen specific for non-small cell lung carcinoma was identified and designated HCAVIII. Subsequently, the antigen was renamed HCAXII and finally renamed LCGA. The antigen was found useful in methods for detection of non-small cell lung cancer and for potential production of antibodies and probes for treatment compositions. These patents include the nucleic acid sequence coding for the cell surface protein LCGA (HCAVIII) which is highly specific for non-small cell lung cancer cells as well as isolated proteins encoded by the nucleic acid sequences.
Three monoclonal antibodies specific for LCGA have now been found. These antibodies can be utilized for both in vivo and in vitro clinical diagnosis of non-small cell lung carcinoma and as target selective carriers for various anti-tumor agents and radioimaging agents.
SUMMARY OF THE INVENTION
In one aspect, the present invention is a monoclonal antibody, an antibody fragment, or a recombinant binding protein thereof which specifically binds to non-small cell lung carcinoma cell antigen LCGA and which has the epitope binding specificity of an antibody produced by the hybridoma cell line 3E10-H10-F12 designated as ATCC NO. HB-12564. A preferred embodiment is the monoclonal antibody secreted by the hybridoma cell line 3E10-H10-F12 (ATCC NO. HB-12564). Another preferred embodiment is an antigen binding fragment derived from the antibody secreted by the hybridoma cell line 3E10-H10-F12 (ATCC NO. HB-12564). Another preferred embodiment is a recombinant binding protein comprising a variable region of the monoclonal antibody secreted by the hybridoma cell line 3E10-H10-F12 (ATCC NO. HB-12564). A most preferred embodiment is a monoclonal antibody, antigen binding fragment or recombinant binding protein thereof which specifically binds to amino acids 173 through 179 of SEQ ID NO:2 or a portion thereof.
In another aspect, the present invention is a hybridoma cell line which produces a monoclonal antibody which binds to non-small cell lung carcinoma cell antigen LCGA and which has the epitope binding specificity of an antibody produced by the hybridoma cell line 3E10-H10-F12 (ATCC NO. HB-12564). A preferred embodiment is the hybridoma cell line 3E10-H10-F12 (ATCC NO. HB-12564).
In another aspect, the present invention is a composition comprising a monoclonal antibody, an antibody fragment, or a recombinant binding protein thereof which specifically binds to amino acids 173 through 179 of SEQ ID NO:2 or a portion thereof or which has the epitope binding specificity of an antibody produced by the hybridoma cell line 3E10-H10-F12 (ATCC NO. HB-12564). In a preferred embodiment, the composition comprises an isolated human
Bollon Arthur P.
Torczynski Richard M.
Bansal Geetha P.
Cytoclonal Pharmaceutics, Inc.
Harris Alana M.
Sidley & Austin
LandOfFree
Methods of detecting non-small cell lung carcinoma and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of detecting non-small cell lung carcinoma and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of detecting non-small cell lung carcinoma and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2495508